BBIO: Late-stage pipeline advances with differentiated launches in ATTR-CM, neuromuscular, and skeletal diseases
Multiple late-stage assets are nearing launch, with Attruby leading in ATTR-CM and strong differentiation supported by clinical and real-world data. BBP-418 and infigratinib are positioned for global launches, while encaleret advances with priority review and broad potential in ADH1 and hypoparathy…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.